Tissue Regenix Group plc (LON:TRX – Get Free Report)’s share price fell 1.7% during trading on Wednesday . The company traded as low as GBX 57 ($0.72) and last traded at GBX 57 ($0.72). 29,893 shares were traded during trading, a decline of 60% from the average session volume of 75,545 shares. The stock had previously closed at GBX 58 ($0.73).
Tissue Regenix Group Stock Performance
The company has a quick ratio of 2.36, a current ratio of 3.74 and a debt-to-equity ratio of 35.69. The firm’s fifty day moving average is GBX 57.17 and its two-hundred day moving average is GBX 61.50. The firm has a market cap of £41.31 million, a P/E ratio of -5,800.00 and a beta of 1.61.
About Tissue Regenix Group
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth.
Read More
- Five stocks we like better than Tissue Regenix Group
- Which Wall Street Analysts are the Most Accurate?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Compound Interest and Why It Matters When Investing
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Utilities Stocks Explained – How and Why to Invest in Utilities
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Tissue Regenix Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group and related companies with MarketBeat.com's FREE daily email newsletter.
